Evidence map›Paper›PMID 37891453›Full record

ReviewInternal and emergency medicine2024

Influenza vaccination for elderly, vulnerable and high-risk subjects: a narrative review and expert opinion.

Raffaele Antonelli Incalzi, Agostino Consoli, Pierluigi Lopalco, Stefania Maggi, Giorgio Sesti, Nicola Veronese, Massimo Volpe

Open access · hybridAbstract readReview
In one paragraph

Review in Internal and emergency medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 1 pooled it
8.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 7 institutions in 1 country.

Raffaele Antonelli IncalziGerontology Unit, Department of Internal Medicine and Geriatrics, Campus Bio-Medico University and Teaching Hospital, Rome, Italy.
Agostino ConsoliDepartment of Medicine and Aging Sciences, "G. d'Annunzio" University, Chieti, Italy.
Pierluigi LopalcoDepartment of Biological and Environmental Sciences and Technologies, University of Salento, Lecce, Italy.
Stefania MaggiInstitute of Neuroscience-Aging Branch, National Research Council, Padua, Italy.
Giorgio SestiDepartment of Clinical and Molecular Medicine, "La Sapienza" University of Rome, Rome, Italy. giorgio.sesti@uniroma1.it.ORCID 0000-0002-1618-7688
Nicola VeroneseDepartment of Internal Medicine, Geriatrics Section, University of Palermo, Palermo, Italy.
Massimo VolpeDepartment of Clinical and Molecular Medicine, "La Sapienza" University of Rome and IRCCS San Raffaele, Rome, Italy.
Istituti di Ricovero e Cura a Carattere Scientifico · ITNational Research Council · ITSapienza University of Rome · ITUniversità Campus Bio-Medico · ITUniversity of Chieti-Pescara · ITUniversity of Palermo · ITUniversity of Salento · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Influenza is associated with a substantial health burden, especially in high-risk subjects such as older adults, frail individuals and those with underlying chronic diseases. In this review, we summarized clinical findings regarding the impact of influenza in vulnerable populations, highlighted the benefits of influenza vaccination in preventing severe illness and complications and reviewed the main evidence on the efficacy, effectiveness and safety of the vaccines that are best suited to older adults among those available in Italy. The adverse outcomes associated with influenza infection in elderly and frail subjects and those with underlying chronic diseases are well documented in the literature, as are the benefits of vaccination (mostly in older adults and in patients with cardiovascular diseases, diabetes and chronic lung disease). High-dose and adjuvanted inactivated influenza vaccines were specifically developed to provide enhanced immune responses in older adults, who generally have low responses mainly due to immunosenescence, comorbidities and frailty. These vaccines have been evaluated in clinical studies and systematic reviews by international immunization advisory boards, including the European Centre for Disease Prevention and Control. The high-dose vaccine is the only licensed influenza vaccine to have demonstrated greater efficacy versus a standard-dose vaccine in preventing laboratory-confirmed influenza in a randomized controlled trial. Despite global recommendations, the vaccination coverage in high-risk populations is still suboptimal. All healthcare professionals (including specialists) have an important role in increasing vaccination rates.

Indexed as

Influenza, HumanInfluenza VaccinesAgedHumansItalyVaccinationVulnerable PopulationsInfluenza VaccinesAgedBurden of diseaseCardiovascular diseasesChronic diseasesDiabetes mellitusInfluenzaInfluenza vaccines

Identifiers

PMID37891453
PMCPMC11039544
OpenAlexW4387971002

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.